NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Drug attack on Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing whether a new drug called BL-M07D1 works better when combined with an existing immunotherapy (pembrolizumab) for people with a specific type of advanced lung cancer that has too much HER2 protein. It will involve about 80 adults whose cancer has spread and c…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New biosimilar drug trial aims to offer more affordable lung cancer treatment
Disease control Recruiting nowThis study is testing whether a proposed biosimilar drug called MB12 works as well as the established drug Keytruda (pembrolizumab) for treating advanced non-squamous non-small cell lung cancer. Both drugs are given in combination with standard chemotherapy. The main goals are to…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Two-Drug attack on advanced lung cancer enters major global trial
Disease control Recruiting nowThis study is testing whether adding a new investigational drug, telisotuzumab adizutecan, to an approved lung cancer drug (osimertinib) works better than the current standard treatment. It is for adults with a specific type of advanced lung cancer that has spread and has an EGFR…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New hope for advanced lung cancer patients in global treatment trial
Disease control Recruiting nowThis global Phase 3 trial is testing whether a new drug called rilvegostomig works better than the standard drug pembrolizumab when both are combined with chemotherapy. It's for people with advanced non-small cell lung cancer that has spread and expresses a specific marker (PD-L1…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New targeted drug enters final testing for Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is comparing a new targeted drug called BL-M07D1 against standard chemotherapy for people with advanced lung cancer that has a specific genetic change called a HER2 mutation. It aims to see if the new drug can better control the cancer and help people live longer witho…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
Brazilian lung cancer treatment patterns revealed in major review
Knowledge-focused Recruiting nowThis study looks back at medical records of 250 Brazilian patients with advanced non-squamous lung cancer whose initial chemotherapy stopped working. Researchers will examine what treatments these patients received next and how they responded. The goal is to understand real-world…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC